Mind Medicine (MindMed) Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MNMD research report →
About the company
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering new treatments for various brain health conditions, encompassing psychiatric disorders, addiction, pain, and neurological ailments. Among its key pipeline assets is MM-120, currently undergoing Phase 2 clinical trials.
- CEO
- Robert Barrow
- IPO
- 2016
- Employees
- 74
- HQ
- Vancouver, BC, CA
Price Chart
- Market Cap
- $1.56B
- P/E
- -17.68
- P/S
- 0.00
- P/B
- 17.24
- EV/EBITDA
- -20.49
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -102.48%
- ROIC
- -60.39%
- Revenue
- $0 · 0.00%
- Net Income
- $-183,793,000 · -69.12%
- EPS
- $-2.06 · -33.77%
- Op Income
- $-166,309,000
- FCF YoY
- -66.26%
- 52W High
- $21.08
- 52W Low
- $4.70
- 50D MA
- $12.71
- 200D MA
- $9.85
- Beta
- 2.62
- Avg Volume
- 2.53M
Get TickerSpark's AI analysis on MNMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 1, 22 | Makes Brigid | other | 361,680 |
| Jun 1, 22 | Makes Brigid | other | 100,308 |
| Jun 1, 22 | Makes Brigid | other | 64,656 |
| May 23, 22 | Greenway Schond L. | other | 1,650,000 |
| May 23, 22 | Greenway Schond L. | other | 1,270,000 |
Our MNMD coverage
Recent articles, reports, and earnings notes.
Want a deeper read on MNMD?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.